Determinants of drug absorption in different ECMO circuits

[1]  D. Tibboel,et al.  Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates , 2010, Clinical pharmacokinetics.

[2]  D. Tibboel,et al.  Haemofiltration in newborns treated with extracorporeal membrane oxygenation: a case-comparison study , 2009, Critical care.

[3]  D. Tibboel,et al.  Microanalysis of β-Lactam Antibiotics and Vancomycin in Plasma for Pharmacokinetic Studies in Neonates , 2008, Antimicrobial Agents and Chemotherapy.

[4]  J. Fortenberry,et al.  Enhanced fluid management with continuous venovenous hemofiltration in pediatric respiratory failure patients receiving extracorporeal membrane oxygenation support , 2008, Intensive Care Medicine.

[5]  David S. Wishart,et al.  DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..

[6]  J. Arnold,et al.  Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment , 2007, Intensive Care Medicine.

[7]  K. Allegaert,et al.  Pharmacotherapy during neonatal extracorporeal membrane oxygenation: toward an evidence-based approach , 2007, Critical care.

[8]  G. Annich,et al.  Sedative clearance during extracorporeal membrane oxygenation , 2005, Perfusion.

[9]  H. Mulla,et al.  Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. , 2005, British journal of clinical pharmacology.

[10]  D. Tibboel,et al.  Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates , 2005, Intensive Care Medicine.

[11]  J. Fortenberry,et al.  Fluid overload before continuous hemofiltration and survival in critically ill children: A retrospective analysis* , 2004, Critical care medicine.

[12]  G. Koren,et al.  Sequestration of fentanyl by the cardiopulmonary bypass (CPBP) , 2004, European Journal of Clinical Pharmacology.

[13]  Graham Lawson,et al.  Pharmacokinetics of Midazolam in Neonates Undergoing Extracorporeal Membrane Oxygenation , 2003, Anesthesiology.

[14]  M. Buck.  Pharmacokinetic Changes During Extracorporeal Membrane Oxygenation , 2003, Clinical pharmacokinetics.

[15]  H. Mulla,et al.  Effects of neonatal extracorporeal membrane oxygenation circuits on drug disposition , 2000 .

[16]  H. Mulla,et al.  In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation , 2000, Perfusion.

[17]  D. Rosen,et al.  Elimination of drugs and toxins during cardiopulmonary bypass. , 1997, Journal of cardiothoracic and vascular anesthesia.

[18]  J. Dipiro,et al.  Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation , 1996, Antimicrobial agents and chemotherapy.

[19]  G. Koren,et al.  Preliminary Studies of the Effects of Extracorporeal Membrane Oxygenator on the Disposition of Common Pediatric Drugs , 1993, Therapeutic drug monitoring.

[20]  D. Rosen,et al.  In vitro variability in fentanyl absorption by different membrane oxygenators. , 1990, Journal of cardiothoracic anesthesia.

[21]  A. Bjorksten,et al.  The effects of cardiopulmonary bypass on plasma concentrations and protein binding of methohexital and thiopental. , 1988, Journal of cardiothoracic anesthesia.

[22]  F. Reynolds,et al.  Extracorporeal circuit sequestration of fentanyl and alfentanil. , 1986, British journal of anaesthesia.